Amgen Shareholder Anemia Drug Suit To Proceed

Law360, New York (February 6, 2008, 12:00 AM EST) -- A federal judge has shot down Amgen Inc.'s bid to duck out of a shareholder lawsuit alleging the biotech company misled investors by concealing the results of a clinical study involving two of its top-selling anemia drugs.

Judge Philip S. Gutierrez of the U.S. District Court for the Central District of California on Friday denied Amgen's motion to dismiss claims by lead shareholder Connecticut Retirement Plans and Trust Funds that positive statements made by company officials regarding the safety of Aranesp and Epogen were knowingly at...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.